Cyrus Poonawalla
Place
-
Now27th
-
Last week26th
-
Two weeks ago26th
-
Three weeks ago28th
- Name
- Cyrus Poonawalla
- Net Worth
- 21.3 Billion USD
- Birth Date
- 11 May 1941
- Age
- 83
- Country
- India
- City
- Pune
- Business
- Healthcare
Cyrus Poonawalla, born on September 26, 1941, in Pune, India, is a prominent Indian billionaire and the founder of the Serum Institute of India (SII), the world's largest vaccine manufacturer by number of doses produced. Cyrus Poonawalla is recognized for his significant contributions to global healthcare through his pioneering work in vaccine production and his philanthropic endeavors.
The Serum Institute of India, founded by Cyrus Poonawalla in 1966, initially started as a small-scale enterprise producing vaccines for the Indian market. Under Poonawalla's visionary leadership, SII expanded its operations and capabilities to become a global powerhouse in vaccine manufacturing. The institute manufactures a wide range of vaccines, including those for polio, measles, influenza, and more recently, COVID-19 vaccines like Covishield (AstraZeneca-Oxford) and Covovax (Novavax).
Cyrus Poonawalla's strategic partnerships with international organizations, governments, and pharmaceutical companies have been instrumental in scaling up vaccine production to meet global demand. His efforts have significantly contributed to immunization programs worldwide, particularly in low- and middle-income countries where access to affordable vaccines is crucial.
Beyond his business achievements, Cyrus Poonawalla is actively involved in philanthropy through the Serum Institute of India Foundation and the Cyrus Poonawalla Group. His charitable initiatives focus on healthcare, education, and community development, aiming to improve the quality of life for underprivileged populations in India and beyond.
Cyrus Poonawalla's entrepreneurial success, dedication to public health, and philanthropic contributions underscore his influence as a transformative figure in the global healthcare sector. His leadership continues to shape the landscape of vaccine production and accessibility, driving progress towards global health equity and disease prevention.
Share
Your involvement